Mary Roederer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mary Roederer has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Howard McLeod
University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 120 Mason Farm Road, CB#7361, Chapel Hill, NC 27599-7361, USA
2 shared publicationsFrancisco Sanchez-Giron
Genomic Diagnostic Laboratory at National Institute of Genomic Medicine (INMEGEN), Alvaro Obregon, Mexico
1 shared publicationGeorge Knafl
University of North Carolina at Chapel Hill, School of Nursing, Carrington Hall Room 5014, CB# 7460, Chapel Hill, NC 27599-7460, USA
1 shared publicationHoward L McLeod
Institute of Pharmacogenomics & Individualized Therapy, UNC Eshelman School of Pharmacy, CB #7361, 120 Mason Farm Road, 1092 Genetic Medicine Building, Chapel Hill, NC, 27599-7361, USA
1 shared publication- Howard L. McLeod
Moffitt Cancer Center, Tampa, FL
1 shared publication - Howard McLeod
Eshelman School of Pharmacy, University of North Carolina, Campus Box 7355, Chapel Hill, NC 27599-7355, USA
1 shared publication
Latest Publications
- 21 March 2013
- Published by Springer Nature in Current Oncology Reports
- Vol. 15 (3) , 276-285
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
Chemotherapy-induced nausea and vomiting is one of the most concerning adverse drug effects from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20–30 % of patients experience breakthrough nausea and vomiting secondary to chemotherapy. To assess the variability of 5-hydroxytryptamine type 3 receptor antagonist efficacy caused by genetic variation, a review of the available literature was conducted. From the literature, three sources of pharmacogenomic variability were identified: polymorphisms associated with 5-hydroxytryptamine type 3 receptor subunits, drug metabolism via cytochromes P450, and drug transport in the body. Testing for receptor subunit polymorphisms is not applicable to a clinical setting at this time; however, cytochrome P450 2D6 testing is FDA-approved and widely accessible. Cytochrome P450 2D6 ultrarapid metabolizers and poor metabolizers displayed altered antiemetic efficacy when compared with intermediate metabolizers and extensive metabolizers. We postulate that testing for cytochrome P450 2D6 phenotypes may be the most accessible way to provide individualized antiemetic therapy in the future.
- 21 March 2013
- Published by Springer Nature in Current Oncology Reports
- Vol. 15 (3) , 276-285
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
Chemotherapy-induced nausea and vomiting is one of the most concerning adverse drug effects from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20–30 % of patients experience breakthrough nausea and vomiting secondary to chemotherapy. To assess the variability of 5-hydroxytryptamine type 3 receptor antagonist efficacy caused by genetic variation, a review of the available literature was conducted. From the literature, three sources of pharmacogenomic variability were identified: polymorphisms associated with 5-hydroxytryptamine type 3 receptor subunits, drug metabolism via cytochromes P450, and drug transport in the body. Testing for receptor subunit polymorphisms is not applicable to a clinical setting at this time; however, cytochrome P450 2D6 testing is FDA-approved and widely accessible. Cytochrome P450 2D6 ultrarapid metabolizers and poor metabolizers displayed altered antiemetic efficacy when compared with intermediate metabolizers and extensive metabolizers. We postulate that testing for cytochrome P450 2D6 phenotypes may be the most accessible way to provide individualized antiemetic therapy in the future.
- 25 August 2012
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 13 (11) , 1307-1313
NAVAGATE: A Rubric to Move from Pharmacogenomics Science to Pharmacogenomics Practice
Integration of pharmacogenomic data at the point of care is the next essential step in translating years of research into evidence-based decisions that impact the care of an individual patient. The use of clinical recommendations for pharmacogenomic data help clinicians to better select and monitor drug therapy. However, a systematic rubric for utilizing the data ensures a thorough implementation of the information in a way that may improve the application of the new scientific discoveries. NAVAGATE is a set of eight questions to ask when considering a pharmacogenomic test or test result when caring for a patient. The series of questions are meant to inform prescribing or dispensing when obtaining or employing pharmacogenomic data for these steps within the medical-care framework. In this article two key examples are used to exemplify the benefits of following a systematic process to evaluate the utility of the new scientific data.
- 25 August 2012
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 13 (11) , 1307-1313
NAVAGATE: A Rubric to Move from Pharmacogenomics Science to Pharmacogenomics Practice
Integration of pharmacogenomic data at the point of care is the next essential step in translating years of research into evidence-based decisions that impact the care of an individual patient. The use of clinical recommendations for pharmacogenomic data help clinicians to better select and monitor drug therapy. However, a systematic rubric for utilizing the data ensures a thorough implementation of the information in a way that may improve the application of the new scientific discoveries. NAVAGATE is a set of eight questions to ask when considering a pharmacogenomic test or test result when caring for a patient. The series of questions are meant to inform prescribing or dispensing when obtaining or employing pharmacogenomic data for these steps within the medical-care framework. In this article two key examples are used to exemplify the benefits of following a systematic process to evaluate the utility of the new scientific data.
- 20 December 2011
- Published by Taylor & Francis in Personalized Medicine
- Vol. 9 (1) , 19-27
Knowledge, Attitudes and Education of Pharmacists Regarding Pharmacogenetic Testing
Pharmacists are positioned to provide medication counseling and drug information to patients. This study assessed the knowledge, attitudes and education of over 700 pharmacists concerning pharmacogenetics and pharmacogenetic testing. A multiquestion, online survey was developed to assess healthcare provider knowledge, attitudes and education concerning pharmacogenetic testing. More than 90% of pharmacists were interested in learning more about pharmacogenetics and testing, with those with less than 10 years of experience were more likely to want web-based continuing education programs. The pharmacists were unlikely to have had formalized education regarding pharmacogenetics, were very likely to rate their knowledge accurately, and were more likely to have a positive attitude about pharmacogenetics if they had received education regarding pharmacogenetics. Most pharmacists were interested in learning more about pharmacogenetic testing.
- 20 December 2011
- Published by Taylor & Francis in Personalized Medicine
- Vol. 9 (1) , 19-27
Knowledge, Attitudes and Education of Pharmacists Regarding Pharmacogenetic Testing
Pharmacists are positioned to provide medication counseling and drug information to patients. This study assessed the knowledge, attitudes and education of over 700 pharmacists concerning pharmacogenetics and pharmacogenetic testing. A multiquestion, online survey was developed to assess healthcare provider knowledge, attitudes and education concerning pharmacogenetic testing. More than 90% of pharmacists were interested in learning more about pharmacogenetics and testing, with those with less than 10 years of experience were more likely to want web-based continuing education programs. The pharmacists were unlikely to have had formalized education regarding pharmacogenetics, were very likely to rate their knowledge accurately, and were more likely to have a positive attitude about pharmacogenetics if they had received education regarding pharmacogenetics. Most pharmacists were interested in learning more about pharmacogenetic testing.
- Open Access
- 1 November 2011
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 89 (11) , 838-845
Can pharmacogenomics improve malaria drug policy?
Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease toxicity, increase effectiveness and reduce the development of drug resistance, thereby lowering health care costs. We review the potential hurdles to developing and implementing pharmacogenetic-guided policies at a national or regional scale for the treatment of uncomplicated falciparum malaria. We also consider current knowledge on some component drugs of artemisinin combination therapies and ways to increase our understanding of host genetics, with the goal of guiding policy decisions for drug selection.
- 1 November 2011
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 89 (11) , 838-845
Open AccessCan pharmacogenomics improve malaria drug policy?
Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease toxicity, increase effectiveness and reduce the development of drug resistance, thereby lowering health care costs. We review the potential hurdles to developing and implementing pharmacogenetic-guided policies at a national or regional scale for the treatment of uncomplicated falciparum malaria. We also consider current knowledge on some component drugs of artemisinin combination therapies and ways to increase our understanding of host genetics, with the goal of guiding policy decisions for drug selection.
- 21 June 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (6) , 897-905
Pharmacogenetics and Rational Drug use Around the World
The WHO embraces evidence-based medicine to formulate an essential medicines list (EML) considering disease prevalence, drug efficacy, drug safety and cost-effectiveness. The EML is used by developing countries to build a national formulary. As pharmacogenetics in developed countries evolves, the Pharmacogenetics for Every Nation Initiative (PGENI) convened with representatives from China, Mexico, Ghana and South Africa in August 2009 to evaluate the use of human pharmacogenetics to enhance global drug use policy. The diseases causing mortality, the lack of integration of pharmacovigilance at the national formulary level, the pharmacogenetics research agenda and pharmacogenetics clinician education did not differ greatly among the countries. While there are many unanswered questions, systematically incorporating pharmacogenetics at the national formulary level promises to improve global drug use.
- 21 June 2011
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (6) , 897-905
Pharmacogenetics and Rational Drug use Around the World
The WHO embraces evidence-based medicine to formulate an essential medicines list (EML) considering disease prevalence, drug efficacy, drug safety and cost-effectiveness. The EML is used by developing countries to build a national formulary. As pharmacogenetics in developed countries evolves, the Pharmacogenetics for Every Nation Initiative (PGENI) convened with representatives from China, Mexico, Ghana and South Africa in August 2009 to evaluate the use of human pharmacogenetics to enhance global drug use policy. The diseases causing mortality, the lack of integration of pharmacovigilance at the national formulary level, the pharmacogenetics research agenda and pharmacogenetics clinician education did not differ greatly among the countries. While there are many unanswered questions, systematically incorporating pharmacogenetics at the national formulary level promises to improve global drug use.
- 20 April 2011
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 45 (4) , 532-538
Global Formulary Review: How Do We Integrate Pharmacogenomic Information?
OBJECTIVE: To summarize a standard formulary decision process and provide recommendations for the integration of pharmacogenomic (PGx) information within the formulary decision-making process. DATA SOURCES: With use of MEDLINE (1920-March 2010), the terms “formularies, hospital” and “pharmacogenetics” were searched in the MeSH database, yielding no results. The MeSH terms were then searched separately in addition to searching for “rational drug therapy” and “essential medicines list” through the main PubMed database. STUDY SELECTION AND DATA EXTRACTION: Articles deemed relevant to both terms were assessed, interpreted, and incorporated as key pieces to the review of formularies and the integration of PGx information as a part of the formulary review process. The articles referenced were deemed appropriate and categorized into 5 areas: formulary management systems and pharmacy and therapeutics (P&T) committees, international formularies, formulary decision-making, PGx evidence, and recommendations regarding integrating PGx into formulary decision-making. DATA SYNTHESIS: The field of PGx is rapidly evolving as the evidence supporting genetically guided individualized therapy continues to grow. To bring this evidence from the bench to the bedside, institutions will need to evaluate PGx data to integrate individualized therapy into practice. Few standardized methods exist to analyze and apply clinical PGx data and incorporate the information into drug evaluation at the formulary level. Several online sites provide resources to aid in formulary review and can be used when incorporating clinically relevant PGx information into a formulary decision. In addition, there are key questions that organizations can ask as they evaluate the PGx information in each step of the decision-making process. CONCLUSIONS: P&T committees should formulate a plan to integrate a search for pharmacogenomic data with each drug evaluation and integrate the results into the formulary decision process to enhance the appraisal of drug efficacy, safety, and cost.
- 20 April 2011
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 45 (4) , 532-538
Global Formulary Review: How Do We Integrate Pharmacogenomic Information?
OBJECTIVE: To summarize a standard formulary decision process and provide recommendations for the integration of pharmacogenomic (PGx) information within the formulary decision-making process. DATA SOURCES: With use of MEDLINE (1920-March 2010), the terms “formularies, hospital” and “pharmacogenetics” were searched in the MeSH database, yielding no results. The MeSH terms were then searched separately in addition to searching for “rational drug therapy” and “essential medicines list” through the main PubMed database. STUDY SELECTION AND DATA EXTRACTION: Articles deemed relevant to both terms were assessed, interpreted, and incorporated as key pieces to the review of formularies and the integration of PGx information as a part of the formulary review process. The articles referenced were deemed appropriate and categorized into 5 areas: formulary management systems and pharmacy and therapeutics (P&T) committees, international formularies, formulary decision-making, PGx evidence, and recommendations regarding integrating PGx into formulary decision-making. DATA SYNTHESIS: The field of PGx is rapidly evolving as the evidence supporting genetically guided individualized therapy continues to grow. To bring this evidence from the bench to the bedside, institutions will need to evaluate PGx data to integrate individualized therapy into practice. Few standardized methods exist to analyze and apply clinical PGx data and incorporate the information into drug evaluation at the formulary level. Several online sites provide resources to aid in formulary review and can be used when incorporating clinically relevant PGx information into a formulary decision. In addition, there are key questions that organizations can ask as they evaluate the PGx information in each step of the decision-making process. CONCLUSIONS: P&T committees should formulate a plan to integrate a search for pharmacogenomic data with each drug evaluation and integrate the results into the formulary decision process to enhance the appraisal of drug efficacy, safety, and cost.
- 1 December 2009
- Vol. 11 (6) , 632-40
Cytochrome P450 enzymes and genotype-guided drug therapy.
The cytochome P450 enzyme system is responsible for the metabolism of xenobiotics, including > 75% of commonly prescribed medications. Many of the cytochrome enzymes exhibit polymorphic genotypes, partly accounting for the variations observed in individual drug responses. Recent advances in the understanding of functional alleles of cytochrome P450 enzymes have changed the use of medications. Improvements in drug efficacy and the prevention of toxicity, as well as improvements in clinical drug dosing, have enhanced pharmacotherapy decisions in medical practice. In addition to personalizing medicine, the identification and quantification of genotypic differences in cytochrome P450 metabolism has the potential to facilitate population-based personalized medicine in countries without the resources to perform genotypic tests at the point of care. This review provides an update on the utility of genotype-guided therapy when treating breast cancer, malaria and coagulation disorders. Also discussed are advancements made in diagnostic tests for cytochrome genotypes and the need for future research in the area of diagnostic tests.
- 1 December 2009
- Vol. 11 (6) , 632-40
Cytochrome P450 enzymes and genotype-guided drug therapy.
The cytochome P450 enzyme system is responsible for the metabolism of xenobiotics, including > 75% of commonly prescribed medications. Many of the cytochrome enzymes exhibit polymorphic genotypes, partly accounting for the variations observed in individual drug responses. Recent advances in the understanding of functional alleles of cytochrome P450 enzymes have changed the use of medications. Improvements in drug efficacy and the prevention of toxicity, as well as improvements in clinical drug dosing, have enhanced pharmacotherapy decisions in medical practice. In addition to personalizing medicine, the identification and quantification of genotypic differences in cytochrome P450 metabolism has the potential to facilitate population-based personalized medicine in countries without the resources to perform genotypic tests at the point of care. This review provides an update on the utility of genotype-guided therapy when treating breast cancer, malaria and coagulation disorders. Also discussed are advancements made in diagnostic tests for cytochrome genotypes and the need for future research in the area of diagnostic tests.
- 1 June 2009
- Vol. 11 (3) , 226-30
Nevirapine hypersensitivity reaction: will the real HLA please stand up?
- 1 June 2009
- Vol. 11 (3) , 226-30
Nevirapine hypersensitivity reaction: will the real HLA please stand up?